NIK-12192

NIK-12192 is an orally active inhibitor of vacuolar H+-ATPase. NIK-12192 reduces intracellular pH, decreases lysosomal volume and acidity, and alters the intracellular localization of V-ATPase by inhibiting proton pumps. NIK-12192 induces αvβ5 integrin polarization, cytoskeletal disruption, cell detachment, anoikis-mediated delayed apoptosis and necrosis, a delayed reduction in mitochondrial membrane potential, and lysosomal/phagosomal accumulation. NIK-12192 inhibits tumor cell migration, invasion, and three-dimensional spheroid growth, and enhances the activity of Topotecan (HY-13768). NIK-12192 suppresses spontaneous lung metastasis in vivo. NIK-12192 is used in research related to colon cancer, ovarian cancer, lung cancer, breast cancer, renal cancer, prostate cancer, acute myeloid leukemia, and melanoma.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • No. CAS: 318262-42-9
  • Fòrmula: C26H31Cl2N3O2
  • Peso molecular:488.45
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Actividad biológica
  • Chemical Information
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00